Breaking Finance News

Zacks Investment Research downgraded Minerva Neurosciences Inc (NASDAQ:NERV) to Hold in a report released today.

Boasting a price of $14.16, Minerva Neurosciences Inc (NASDAQ:NERV) traded -1.14% lower on the day. With the last close up 38.88% from the two hundred day average, compared with the Standard & Poor's 500 Index which has decreased -0.01% over the same period. Minerva Neurosciences Inc has recorded a 50-day average of $13.37 and a two hundred day average of $9.98. Volume of trade was down over the average, with 193,956 shares of NERV changing hands under the typical 331,026

Zacks Investment Research has downgraded Minerva Neurosciences Inc (NASDAQ:NERV) to Hold in a statement released on 10/05/2016.

On 05/12/2016, Jefferies & Co released a statement about Minerva Neurosciences Inc (NASDAQ:NERV) raised the target price from $0.00 to $10.00 that suggested an upside of 0.65%.

Performance Chart

Minerva Neurosciences Inc (NASDAQ:NERV)

Minerva Neurosciences Inc has 52 week low of $3.45 and a 52 week high of $15.84 and has a market capitalization of $0.

Also covering Minerva Neurosciences Inc's target price, a total of 1 firm has released a report on Minerva Neurosciences Inc. The 12-month price target is $10.00 with 1 broker rating the company a strong buy, one firm rating the stock a buy, 0 analysts rating the company a hold, zero equity analysts rating the company a underperform, and lastly zero brokerages rating the company a sell.

More About Minerva Neurosciences Inc (NASDAQ:NERV)

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company's product portfolio include MIN-101 for the treatment of schizophrenia; MIN-117 for the treatment of major depressive disorder (MDD); MIN-202 (also known as JNJ-42847922) for the treatment of insomnia disorder and adjunctive MDD, and MIN-301 for the treatment of Parkinson's disease. MIN-101 blocks serotonin receptors and sigma receptors, over two receptors in the brain that are involved in the regulation of mood, cognition, sleep and anxiety. MIN-117 is meant to block a specific subtype of serotonin receptor called 5-HT1A. MIN-202 is a selective orexin 2 receptor antagonist it is developing in collaboration with Janssen Pharmaceutica NV. MIN-301 is a soluble recombinant form of the Neuregulin-1b1 protein.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *